VIP Class Notes (Li)[W]

Today we focused on:

Translating interview notes

Vocabulary

In contrast/on the other hand/meanwhile/alternatively

Grammar

need to have efficient – need to be efficient 

face the client – present to the client

Writing

…Payer is more concerned about the total cost of the drug,daily cost is supposed to not exceed 10RMB/day if the duration of treatment(DOT) is long-term, while if the duration of treatment is within 1 week , the price should be higher… And if the DOT is around 2~3months, 1000RMB per year is acceptable for most patients…

Revised: 

The payer is more concerned of the total cost of the drug. If the duration of treatment (DOT) is long-term,  the daily cost should not exceed 10RMB/day. On the other hand, if the duration of treatment is within 1 week, the price should be higher. In addition, if the DOT is around 2-3months, 1000RMB/per year is acceptable to most patients.

“…I think 10RMB/day is reasonable for this drug referring to other chronic disease like hypertension which the previously daily cost is around 6~7 RMB, and in a NRDL negotiation, Payer would comprehensively consider the competitors’ price, other chronic disease cost and international price etc. to determine the price…”

Revised: 

I think 10RMB/day is reasonable for this drug when compared to previous prices of other chronic diseases like hypertension where the daily cost was around 6-7RMB. In a NRDL negotiation, the payer would consider comprehensively the competitors’ price, the cost of other chronic diseases and the international price etc. to set the price.  

“…So far, there is no drug available for patients with refractory chronic cough, this drug sounds pretty good. Some CC patients are painful, but they don’t receive enough social attention as cough isn’t an life-threatening disease like cancer…”

Revised: 

…So far, there is no drug available for patients with refractory chronic cough, this drug sounds pretty good. Some CC patients are in pain/are suffering, but they don’t receive enough care as the cough isn’t a life-threatening disease like cancer…”

Revised: 
“…The efficacy is not bad, with a 37% (over 1/3 ) reduction in cough frequency, which demonstrates it’s effectiveness … and the on-set time of less than 2 weeks is acceptable for those patients with RCC…”

“… Normal review cycle is around 2 ~ 3 years while the negotiation is dynamically adjusted. For the normal review pathway, these drugs are generally widely used and recognized by HCPs while for the negotiation pathway, which requires the approvals from doctors and a reasonable price. Compared to Normal review, Negotiation could accelerate NRDL listing… “

Revised:

“… The normal review cycle is around 2 ~ 3 years while the negotiation is dynamically adjusted. For the normal review pathway, these drugs are generally widely used and recognized by HCPs. In contrast, for the negotiation pathway, it requires the approval from doctors and a reasonable price. Compared to Normal review, the negotiation could accelerate NRDL listing… “

“… If Gefapixant didn’t succeed in NRDL negotiation before the generic drug was launched, it might requrie normal review to enter NRDL…It is better to be listed in NRDL before generics was launches, as NRDL implementation will get supports from Medical insurance bureaus nationwide, which will speed up hospital listing…”

Revised: 

“… If Gefapixant doesn’t succeed in the NRDL negotiation before the generic drug is launched, it may require normal review to enter NRDL…It is better to be listed in NRDL before generics launch, as NRDL implementation will get support from Medical insurance bureaus nationwide, which will speed up hospital listing…”

“Gefapixant might not be listed in NRDL earlier than generics if it miss the window period.
Negotiation would accelerate NRDL listing of Gefapixant, which could help build an advantage before generics launch “

Revised: 

“Gefapixant might not be listed in NRDL earlier than generics if it misses the window of opportunity. Negotiation would accelerate NRDL listing of Gefapixant, which could help create an advantage before generics launch “